<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>BELEODAQ (belinostat) for injection - for Healthcare Professionals (HCPs)</title>
    <meta name="description" content="In the next round against relapsed or refractory PTCL, fight on with BELEODAQ. It is an HDAC inhibitor available for relapsed/refractory PTCL.">
    <!-- Favicon -->
    <link rel="icon" href="https://beleodaq.com/hcp/wp-content/uploads/2019/05/cropped-favicon-Beleodaq-32x32.png" sizes="32x32">
    <!-- Google fonts -->
    <link rel="preconnect" href="https://fonts.gstatic.com">
    <link href="https://fonts.googleapis.com/css2?family=Open+Sans:wght@300;400;600;700;800&family=Raleway:wght@700&display=swap" rel="stylesheet">
    <!-- Font Awesome CDN -->
    <script src="https://kit.fontawesome.com/2d2e2839ee.js" crossorigin="anonymous"></script>
    <!-- CSS Reset -->
    <link rel="stylesheet" href="css/reset.css">
    <!-- Stylesheet -->
    <link rel="stylesheet" href="css/index.css">
</head>
<body>
    <!-- Header -->
    <header class="header">
        <!-- Indications and Usage -->
        <div class="indications">
            <h5 class="indications__title">Indications and Usage</h5>
            <p class="indications__body copyright">BELEODAQ is a histone deacetylase inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon veriﬁcation and description of clinical beneﬁt in the conﬁrmatory trial.<sup>1</sup></p>
        </div>
        <!-- Navigation -->
        <nav class="nav">
            <!-- Logo -->
            <a class="nav__logo" href="index.html">
                <img src="assets/svg/beleodaq-logo.svg" alt="BELEODAQ® (belinostat) for injection: For injection in the treatment of relapsed or refractory PTCL" />
            </a>
            <!-- Header Buttons -->
            <div class="nav__buttons">
                <!-- Site Buttons (redirecting to other parts of site) -->
                <ul class="site-buttons">
                    <li>
                        <a class="site-buttons__button p" href="#">
                            Important Safety Information
                        </a>
                    </li>
                    <li>
                        <a class="site-buttons__button p"
                        href="#">
                           Prescribing Information
                        </a>
                    </li>
                    <li>
                        <a class="site-buttons__button button--orange p" href="#">
                           Patient Site
                        </a>
                    </li>
                </ul>
                <!-- Mobile Logo -->
                <a class="mobile__logo" href="index.html">
                    <img src="assets/svg/beleodaq-logo.svg" alt="BELEODAQ® (belinostat) for injection: For injection in the treatment of relapsed or refractory PTCL" />
                </a>
                <!-- Nav Links and Dropdown Menus -->
                <button class="mobile__button">
                    <img src="assets/svg/menu/bars.svg" alt="hamburger menu button" class="mobile__button__icon"/>
                </button>
                <ul class="navlinks">
                    <li>
                        <a class="navlinks__link p" href="ptcl.html">PTCL <br>Overview</a>
                    </li>
                    <li>
                        <a class="navlinks__link p" href="about.html">About <br>Beleodaq</a>
                    </li>
                    <li>
                        <a class="navlinks__link p" href="inclusion-criteria.html">BELIEF <br>Trial</a>
                    </li>
                    <li>
                        <a class="navlinks__link p" href="efficacy.html"><br>Efficacy</a>
                        <ul class="dropdown dropdown--hidden">
                            <li>
                                <a href="" class="dropdown__item p">
                                    Study design
                                </a>
                            </li>
                            <li>
                                <a href="" class="dropdown__item p">
                                    Baseline Characteristics
                                </a>
                            </li>
                            <li>
                                <a href="" class="dropdown__item p">
                                    Response Rate
                                </a>
                             </li>
                            <li>
                                <a href="" class="dropdown__item p">
                                    Duration of Response
                                </a>
                            </li>
                        </ul>
                    </li>
                    <li>
                        <a class="navlinks__link p" href="safety.html">Safety & Tolerability</a>
                        <ul class="dropdown dropdown--hidden">
                            <li>
                                <a href="" class="dropdown__item p">
                                    Adverse Reactions
                                </a>
                            </li>
                            <li>
                                <a href="" class="dropdown__item p">
                                    Tolerability
                                </a>
                            </li>
                        </ul>
                    </li>
                    <li>
                        <a class="navlinks__link p" href="dosing.html">Dosing & Administration</a>
                        <ul class="dropdown dropdown--hidden">
                            <li>
                                <a href="" class="dropdown__item p">
                                    Dosing Schedule
                                </a>
                            </li>
                            <li>
                                <a href="" class="dropdown__item p">
                                    Dose Modifications
                                </a>
                            </li>
                        </ul>
                    </li>
                    <li>
                        <a class="navlinks__link p" href="access.html">Access & Resources</a>
                        <ul class="dropdown dropdown--hidden">
                            <li>
                                <a href="" class="dropdown__item p">
                                    STAR
                                </a>
                            </li>
                            <li>
                                <a href="" class="dropdown__item p">
                                    Resources
                                </a>
                            </li>
                        </ul>
                    </li>
                    <li>
                        <a class="navlinks__link p" href="contact.html">Contact <br>Us</a>
                    </li>
                </ul>
            </div>
        </nav>
    </header>
    <!-- Main -->
    <main>
        <h2 class="primary">Acrotech Biopharma Terms of Use</h2>
        <p class="dark light">The information provided on this Acrotech Biopharma, LLC. Website is for general informational and educational use only and is subject to the following terms and conditions. By accessing and using this website, you acknowledge and accept, without limitation or qualification, this Terms of Use Agreement. If you do not wish to be bound by this agreement, you may not access or use any materials on this website.
        </p>

        <p class="dark light">
            <span class="semibold secondary-variant">1. Scope of Use.</span>
            Acrotech Biopharma, LLC. (“Acrotech”) maintains this website for your personal information and education. The information, documents and related graphics are available for your personal use, provided that the materials are not modified in any way and all copyright and other proprietary notices contained on the provided materials are maintained. This website and all its contents are intended to comply with United States laws that it may be subject to and Acrotech makes no representation that the information is appropriate for use in locations outside of the United States. Other countries may have laws, regulatory requirements, and medical practices that differ from those in the U.S. Those who access this site from other locations do so on their own initiative and are responsible to comply with applicable local laws and regulations. Any offer, product, or service available through this website is void where prohibited.
        </p>
        <p class="dark light">
            <span class="semibold secondary-variant">2. Intellectual Property.</span>
            Images and materials displayed on this website are subject to intellectual property laws. Nothing contained herein shall be construed as conferring by implication, estoppel or otherwise any license or right under any patent, trademark, or copyright owned by Acrotech or any third party. Except as expressly provided herein, no use of any Acrotech intellectual property rights may be made without prior written consent of Acrotech. In addition, Acrotech neither warrants nor represents that the use of images or materials from this website will not infringe the rights of third parties not owned by or affiliated with Acrotech.
        </p>
        <p class="dark light">
            <span class="semibold secondary-variant">3. Medical Information.</span>
            The medical information provided on this website is for educational and informational purposes only and not meant to be a substitute for advice offered by a physician or other healthcare professional. If medical advice or services are desired, please consult your physician or health care provider.
        </p>
        <p class="dark light">
            <span class="semibold secondary-variant">4. Non-Confidential Information.</span>
            Any oral, written or electronic response or communication established with Acrotech by any user of this website shall be deemed as non-confidential. Acrotech shall not have any obligations of any kind with respect to such information and shall be free to use any ideas, concepts, know-how or techniques contained in such communication without restriction for any purpose whatsoever. The sender of such information is fully responsible for its content, including, without limitation, its accuracy and truthfulness and its non-infringement of another party’s proprietary rights.
        </p>
        <p class="dark light">
            <span class="semibold secondary-variant">5. Forward-Looking Statements.</span>
            This website may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on the beliefs of Spectrum’s management as well as assumptions made by and information currently available to Acrotech’s management. Readers should not put undue reliance on these forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Acrotech’s actual results may differ materially from the results projected in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed in the documents and reports filed by the Spectrum from time to time with the Securities and Exchange Commission, specifically the most recent Form 10-K and 10-Q.
        </p>
        <p class="dark light">
            <span class="semibold secondary-variant">6. Disclaimer of Warranties.</span>
            While Acrotech uses reasonable efforts to include accurate and up-to-date information in this site, we make no warranties or representations of any kind as to the accuracy, currency or completeness of the information provided. We assume neither responsibility for any errors or omissions in the content of this site nor any liability to update the information contained in this site. Acrotech provides this information “as is” and disclaims all warranties of any kind, both express and implied, including, but not limited to, merchantability, fitness for a particular purpose, or non-infringement. Please note that some jurisdictions do not allow the exclusion of implied warranties, so the above disclaimer may not apply to you.
        </p>
        <p class="dark light">
            <span class="semibold secondary-variant">7. Limitations of Liability.</span>
            Use of this site is at the user’s own risk. Neither Acrotech nor any other party involved in the creating, producing, or delivering the website is liable for any direct, incidental, consequential, indirect or punitive damages arising out of access to or use of this website and/or the information provided, regardless of whether Acrotech has been advised as the possibility of such damages.
        </p>
        <p class="dark light">
            <span class="semibold secondary-variant">8. Third Party Websites and Links.</span>
            This site may contain references or links to other websites maintained by third parties not under Acrotech’s control. Such references or links are provided merely for convenience and Acrotech makes no representations or warranties of any kind with respect to any third party site. The inclusion of the reference or link does not imply endorsement of the site and Acrotech is not liable for any damages or injuries of any kind arising from such content or information.
        </p>
        <p class="dark light">
            <span class="semibold secondary-variant">9. Governing Law.</span>
            This Terms of Use Agreement and your use of this website shall be governed by the laws of the United States and the State of California without regard to its conflicts of law provisions. Any legal action or proceeding arising from or relating to your access or use of this website shall be brought exclusively in a federal or state court of proper jurisdiction in the State of California.
        </p>
        <p class="dark light">
            <span class="semibold secondary-variant">10. Modifications.</span>
            Acrotech Biopharma reserves the right to revise the terms and conditions of this agreement at any time without notice and such changes will be deemed effective upon posting. Continued use of the website following posting of an amended Terms of Use will indicate acceptance of such changes and therefore, this agreement should be reviewed periodically.
        </p>
        <p class="dark light">© 2021 Acrotech Biopharma, LLC. All rights reserved.</p>
    </main>
    <!-- ISI -->
    <footer>
        <section class="isi">
            <div>
                <h5 class="isi__header">Select Important Safety Information</h5>
                <p class="isi__body light"><span class="isi__body--bold ">Warnings and Precautions</span>
                BELEODAQ can cause thrombocytopenia, leukopenia (neutropenia and lymphopenia), and/or anemia; monitor blood counts weekly during treatment, and modify dosage as necessary.</p>
            </div>
            <a class="isi__button more" onclick="scrollToFooter()" href="javascript:;">
                See More <i class="fas fa-arrow-down"></i>
            </a>
            <a class="isi__button less hidden" onclick="scrollBack()" href="javascript:;">
                See Less <i class="fas fa-arrow-up"></i>
            </a>
        </section>
        <section class="hidden">
            <h5 class="primary">Indications and Usage</h5>
            <ul>
                <li>
                    <p class="light">BELEODAQ is a HDAC inhibitor indicated for the treatment of patients with R/R PTCL</p>
                </li>
                <li>
                    <p class="light">This indication is approved under accelerated approval based on tumor response rate and DoR. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.
                    </p>
                </li>
            </ul>
            <div class="warnings-and-precautions">
                <h5 class="primary">Warnings and Precautions</h5>
                <p class="light"><span class="semibold">Hematologic Toxicity:</span> BELEODAQ can cause thrombocytopenia, leukopenia (neutropenia and lymphopenia), and/or anemia; monitor blood counts weekly during treatment and modify dosage as necessary.</p>
                <p class="light"><span class="semibold">Infections:</span> Serious and sometimes fatal infections, including pneumonia and sepsis, have occurred with BELEODAQ. Do not administer BELEODAQ to patients with an active infection. Patients with a history of extensive or intensive chemotherapy may be at a higher risk of life-threatening infections.</p>
                <p class="light"><span class="semibold">Hepatotoxicity:</span> BELEODAQ can cause fatal hepatotoxicity and liver function test abnormalities. Monitor liver function tests before treatment and before the start of each cycle. Interrupt or adjust dosage until recovery, or permanently discontinue BELEODAQ based on the severity of the hepatic toxicity.</p>
                <p class="light"><span class="semibold">Tumor Lysis Syndrome:</span> Tumor lysis syndrome has occurred in BELEODAQ-treated patients in the clinical trial of patients with relapsed or refractory PTCL. Monitor patients with advanced stage disease and/or high tumor burden, and take appropriate precautions.</p>
                <p class="light"><span class="semibold">Gastrointestinal Toxicity:</span> Nausea, vomiting, and diarrhea occur with BELEODAQ and may require the use of antiemetic and antidiarrheal medications.</p>
                <p class="light"><span class="semibold">Embryo-Fetal Toxicity:</span> BELEODAQ can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the risk to a fetus. Advise females of reproductive potential to use an effective method of contraception during treatment with BELEODAQ and for 6 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with BELEODAQ and for 3 months after the last dose.</p>
            </div>
            <h5 class="primary">Adverse Reactions</h5>
            <ul>
                <li>
                    <p class="light">The most common adverse reactions observed in more than 25% of patients with relapsed or refractory PTCL in the trial, who were treated with BELEODAQ, were nausea (42%), fatigue (37%), pyrexia (35%), anemia (32%), and vomiting (29%).</p>
                </li>
                <li>
                    <p class="light">Sixty-one patients (47.3%) experienced serious adverse reactions while taking BELEODAQ or within 30 days after their last dose of BELEODAQ. The most common serious adverse reactions (>2%) were pneumonia, pyrexia, infection, anemia, increased creatinine, thrombocytopenia, and multi-organ failure.</p>
                </li>
            </ul>
            <h5 class="primary">Drug Interactions</h5>
            <ul>
                <li>
                    <p class="light">BELEODAQ is primarily metabolized by UGT1A1. Avoid concomitant administration of BELEODAQ with strong inhibitors of UGT1A1.</p>
                </li>
            </ul>
            <div class="specific-populations">
                <h5 class="primary">Use in Specific Populations</h5>
                <p class="light"><span class="semibold">Lactation:</span> Due to the potential for serious adverse reactions in the breastfed child, advise patients that breastfeeding is not recommended during treatment with BELEODAQ and for 2 weeks after the last dose.</p>
                <p class="light"><span class="semibold">Pregnancy Testing:</span> BELEODAQ can cause fetal harm when administered to a pregnant woman. Pregnancy testing is recommended for females of reproductive potential prior to initiating BELEODAQ.</p>
                <p class="light"><span class="semibold">Pediatric Use:</span> The safety and effectiveness of BELEODAQ in pediatric patients have not been established.</p>
            </div>
            <a href="#">
                <p class="semibold">
                Please see full Prescribing Information for BELEODAQ.
                </p>
            </a>
            <p class="light">You are encouraged to report negative side effects of prescription drugs to the FDA. Visit <span class="secondary-variant semibold">www.fda.gov/medwatch</span> or call <span class="secondary-variant semibold">1-800-FDA-1088 (1-800-332-1088)</span>. You also may contact Acrotech Biopharma, LLC at <span class="secondary-variant semibold">1-888-292-9617</span>.</p>
            
            <h5 class="primary">References</h5>
            <p class="light">1. BELEODAQ®[Prescribing Information], AcrotechBiopharma, LLC; January 2020. 2. O’Connor O, et al. J Clin Oncol. 2015;33:2492-2499. 3. Vose JM, et al. J Clin Oncol. 2008;26:4124-4130. 4. Carson KR, et al. Cancer. 2017;123:1174-1183. 5. LansiganF, et al. Acta Haematol. 2020;143:40-50. 6. BelleiM, et al. Haematologica. 2018;103:1191-1197. 7. Li W, et al. Int J Mol Sci. 2019;20. doi:10.3390/ijms20071616. 8. Milazzo G, et al. Genes. 2020;11. doi:10.3390/genes11050556. 9. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for T-Cell Lymphomas V.1.2021. © 2021 National Comprehensive Cancer Network, Inc. All rights reserved. Accessed February 25, 2021. The NCCN Guidelines® and illustrations herein may not be reproduced in any form for any purpose without the express written permission of NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org. The NCCN Guidelines are a work in progress that may be refined as often as new significantdata becomes available. 10. Savage KJ, et al. Blood. 2014:124:3075. doi.org/10.1182/blood.V124.21.3075.3075.</p>
            <div class="footer__bottom">
                <img src="assets/images/acrotech-logo.png" alt="Acrotech Biopharma Logo" />
                <p class="light">
                    © Acrotech Biopharma, LLC. 2019. All rights reserved.<br>
                    Information on this website is intended for U.S. residents.<br>
                    BEL-XXX. June 2021.
                </p>
                <div class="bottom_col">
                    <p class="light">Contact Information U.S.</p>
                    <p class="light">Privacy Policy</p>
                    <p class="light">Linking Policy</p>
                </div>
                <div class="bottom_col">
                    <p class="light">Terms of Use</p>
                    <p class="light">Trademark Policy</p>
                    <p class="light">Full Prescribing Information</p>
                </div>
            </div>
        </section>
    </footer>
    <!-- Vanilla JS -->
    <script src="js/app.js"></script>
</body>
</html>